Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Michael Howley PA-C, MBA, PhD
Advertisement
Articles by Michael Howley PA-C, MBA, PhD
Survey taken by pharma and CRO executives evaluates attributes of large datasets.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
How a Shift Towards Oral Medications Impacts GLP-1s
5